



## Tvardi Therapeutics to Participate at the 2024 BTIG Virtual Biotechnology Conference

July 31, 2024

Houston, TX – July 31, 2024 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that Imran Alibhai, PhD, Chief Executive Officer of Tvardi Therapeutics will participate in a fireside chat at the 2024 BTIG Virtual Biotechnology Conference on Tuesday, August 6, 2024, at 10:00 AM ET.

In addition to the fireside chat, the management team will hold one-on-one investor meetings Monday and Tuesday, August 5-6, 2024. If you are interested in meeting with the Tvardi Therapeutics management team during the conference, please reach out to [BTIG](#).

About Tvardi Therapeutics Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company is conducting Phase 2 clinical trials in STAT3-driven diseases: hepatocellular carcinoma ([NCT05440708](#)) and idiopathic pulmonary fibrosis ([NCT05671835](#)). To learn more, please visit [tvardi.com](https://tvardi.com) or follow us on [LinkedIn](#) and [X \(Twitter\)](#).

**Contact:**

Tvardi Investor Relations  
Sara Manning  
[ir@tvardi.com](mailto:ir@tvardi.com)